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Oestrogen action is mediated via speciﬁc receptors that act as ligand-activated transcription factors. A monoclonal antibody
speciﬁc to the C-terminus of human oestrogen receptor beta has been characterized and the prevalence of expression of
oestrogen receptor beta protein investigated in a well deﬁned set of breast cancers. Reverse transcription-polymerase chain
reaction analysis of RNA from tissue biopsies detected oestrogen receptor beta in all samples examined. The anti-oestrogen
receptor beta antibody cross reacted speciﬁcally with both long (*59 Kd) and short (*53 Kd) forms of recombinant
oestrogen receptor beta. Western blot analysis of breast tumours contained both forms of oestrogen receptor beta protein
although in some samples lower molecular weight species (32–45 Kd) were identiﬁed. Fifty-one breast cancer biopsies were
examined using immunohistochemistry; 41 (80%) were immunopositive for oestrogen receptor alpha, 48 (94%) were
immunopositive for oestrogen receptor beta and 38 (74.5%) co-expressed both receptors. Expression of oestrogen receptor
beta was exclusively nuclear and occurred in multiple cell types. There was no quantitative relationship between staining for
the two ERs although in tumours in which both receptors were present immunoexpression of oestrogen receptor alpha was
invariably more intense. The signiﬁcance of oestrogen receptor beta protein expression in breast cancers to therapy remains
to be determined but the availability of a well characterized antibody capable of detecting oestrogen receptor beta in archive
material will facilitate the process.
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Until recently it was accepted that the major effects of oestrogen on
the growth and development of the breast and its tumours was
mediated through a single oestrogen receptor (ERa, Green et al,
1986). Ligand binding assays and immunohistochemical studies
indicated that most breast tumours possessed such receptors and
their presence was associated with the likelihood of response to
endocrine therapy (McGuire et al, 1982; Jordan et al, 1988; Miller,
1996). However in 1996 an additional ER isotype, usually known as
ERb, was identiﬁed in rat (Kuiper et al, 1996) and human (Mossel-
man et al, 1996). Both receptors share signiﬁcant sequence
homology within their DNA and ligand binding domains but are
encoded on different chromosomes (Enmark et al, 1997). Studies
in vitro have demonstrated that although both ERa and ERb bind
oestradiol with equal afﬁnity (Kuiper et al, 1997) these receptors
may have differential responses to some oestrogen agonists and
antagonists (Watanabe et al, 1997; Barkhem et al, 1998; Jones et
al, 1999; Sun et al, 1999). Notably ERb appears to have a higher
afﬁnity for phytoestrogens, including genestein, than does ERa
(Kuiper et al, 1997). When present within in the same cell, ERa
and ERb have the capacity to form either homo- or heterodimers
(Pace et al, 1997) and the proportions of the different isotypes may
be critical to modulation of gene expression (Hall and McDonnell,
1999). Studies in mammary tissues of the rat have suggested that
one role of ERb may be to antagonize ERa-mediated actions in
epithelial cells (Saji et al, 2000), a function supported by data from
in vitro cell transfections (Hall and McDonnell, 1999).
To date studies demonstrating the expression of ERb in breast
cancer tissues have largely been conﬁned to the demonstration of
expression of ERb mRNA (Dotzlaw et al, 1997; Leygue et al,
1998; Speirs et al, 1999; Vladusic et al, 2000). Messenger RNAs
encoding variant forms of both ERa (Bollig and Miksicek, 2000)
and ERb (Lu et al, 1998) have been identiﬁed in breast cancers
and in breast cancer cell lines and there has been considerable
debate over the role of such variants in cancer progression
(Balleine et al, 1999; Huang et al, 1999).
The present investigation was designed to characterize the
expression of ERb and ERa proteins in a series of 51 breast
cancers; some samples were also subjected to analysis for
mRNAs by RT–PCR. We have made use of speciﬁc mono-
clonal antibodies and used both immunohistochemistry on
well-ﬁxed tissues in which the cellular architecture has been
preserved as well as Western analysis of tissue extracts. These
investigations have demonstrated wide spread expression of
ERb protein and provide new information important for
further exploration of the relationship between the co-expres-
sion of ERb and ERa and the in response of breast
cancers to endocrine therapies.
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Patients and tissue samples
Samples of breast were obtained from 51 consecutive patients
presenting to the Edinburgh Breast Unit with diagnosis of breast
cancer who had given informed consent for tissue to be used for
research purposes. Samples were snap frozen to provide material
for extraction of RNA or protein, or ﬁxed in 10% neutral buffered
formaldehyde for 16 to 24 h then stored in 70% (w v
71) ethanol
prior to processing into parafﬁn wax at the Department of Pathol-
ogy using standard procedures.
Detection of ERa and ERb by reverse transcription-
polymerase chain reaction (RT–PCR)
RNA was extracted using the Tri-reagent system according to the
manufacturer’s instructions (Sigma, Poole, Dorset, UK), dissolved
in RNase-free water and stored at 7708C. One microgram of
RNA was reverse transcribed for 1 h at 428C in a 20-ml reaction
using the Superscript system (Gibco-BRL, Paisley, Scotland, UK).
Upon completion of the incubation, the sample cDNAs were each
diluted to a ﬁnal volume of 60 ml, and 20 ml used in individual
PCR reactions containing primers speciﬁc for ERa,E R b or
alpha-actin (positive control). The primers employed were as
follows: human ERa (Green et al, 1986), forward 5'-GGCCAGTAC-
CAATGACAAGGGAAG-3' (nucleotides 787–811); ERa, reverse 5'-
CCAGCAAGCATGTCGAAGATCTCC-3' (nucleotides 1558–1580);
human ERb (Ogawa et al, 1998a), forward 5'-GTTGC-
GCCAGCCCTGTTAC-3' (nucleotides 493–512); ERb, reverse 5'-
CTCGTCGGCACTTCTCTGTCTC-3' (nucleotides 788–809);
alpha-actin forward, 5'-GGAGCAATGATCTTGATCTT-3'; alpha-
actin reverse, 5'-CCTTCCTGGGCATGGAGTCCT-3'. The primers
used to amplify the oestrogen receptor cDNAs were chosen to span
regions separated by two intronic regions. PCR reactions were
carried out using ‘Hot start’ Taq polymerase (Qiagen, Crawley,
West Sussex, UK) and the following cycling conditions; 968C for
30 s, 568C for 1 min, 728C for 1 min, repeated for 30 cycles for
ERa, similar conditions were used for ERb except that the anneal-
ing temperature was 528C. The expected sizes of the ampliﬁed
bands were; ERa, 793 bp; ERb, 316 bp; alpha actin 120 bp. Nine
samples were analyzed.
Antibodies
The anti-hERa mouse monoclonal antibody (code 1D5) was
obtained from DAKO (Cambridge, UK). A peptide located at the
C-terminus of hERb (Mosselman et al, 1996) (CSPAEDSKS-
KEGSQNPQSQ) was used to prepare a monoclonal antibody in
mice according to standard methods and positive clones were iden-
tiﬁed by ELISA using recombinant human ERb (P2466, PanVera,
Madison, WI, USA) (Saunders et al, 2000). This antibody has been
used previously to demonstrate expression of ERb using human
ovarian tissue sections (Saunders et al, 2000).
Western analysis
Two forms of recombinant human ERb1 were obtained from Pan
Vera (Madison, WI, USA). These were hERb1 ‘short’, a *53 Kd
form of the receptor (bs) synthesized from a cDNA (Mosselman
et al, 1996) lacking the ﬁrst potential start site for translation
(Ogawa et al, 1998a), and hERb1 ‘long’ (bL) the larger protein
(*59 Kd) synthesized from the full length cDNA (Ogawa et al,
1998a). Recombinant hERa (*66 Kd) was also obtained from
Pan Vera. Gel analysis and blotting were carried out as described
previously (Saunders et al, 2000). Brieﬂy, proteins were extracted
from frozen biopsy specimens by rapid homogenization of tissue
in denaturing/loading buffer (50 mM Tris-HCl pH 6.8, 100 mM
DTT, 2% SDS, 0.1% bromophenol blue, 10% glycerol, all from
Sigma). Recombinant proteins (0.5 mg lane
71), tissue extracts
(30–50 mg total protein) and prestained protein molecular weight
markers (BioRad) were separated on denaturing minigels contain-
ing an acrylamide gradient from 4 to 20% (w v
71) polyacrylamide
(Novex, San Diego, CA, USA). Membranes were incubated over-
night with the mouse monoclonal anti hERb1 (code M9) at 1 in
500 or mouse monoclonal anti-hERa (code1D5) at 1 in 100; both
the antibodies were diluted in TBST containing 5% normal donkey
serum. Bound antibodies were detected using rabbit anti-mouse
IgG and the ECL visualization system (Amersham, Bucks, UK)
according to the manufacturer’s instructions.
Immunohistochemistry
Sections (4 mm) were mounted on Superfrost coated slides (BDH,
Poole, Dorset, UK) dewaxed and rehydrated in gradient alcohols
and distilled water. Endogenous peroxidases were blocked with
3% hydrogen peroxide for 10 min and sections were subjected to
heat-induced antigen retrieval in 0.01 m citrate buffer, pH 6.0
(Norton et al, 1994) before staining with speciﬁc antibodies as
outlined below.
Anti-ERa All staining for ERa was carried out in the Pathology
Department of the Western General Hospital. An endogenous
biotin block was carried out by applying 100 ml egg white blocking
solution for 30 min. Anti-ERa, (Dako) was diluted 1 in 50 in
biotin diluent for primary antibodies (PBS, goat serum and d-
biotin), and incubated in the sections for 60 min at room tempera-
ture. The secondary antibody, biotinylated anti-mouse Ig(Vector
Laboratories) was diluted 1:2000, in ‘background reducing diluent’
(Dako) and applied to sections for 30 min at room temperature.
The tertiary system (ABC-HRP, Dako) was applied as per manufac-
turer’s instructions for 30 min at room temperature. The tissue was
visualized by immersing sections in 3,3'-diaminobenzidine tetra-
hydrochloride (DAB) for 5 min. Sections were counterstained
using Mayers haematoxylin (Sigma-Aldrich, Poole, Dorset), dehy-
drated through gradient alcohols and mounted.
Anti-ERb Immunolocalization was undertaken as described in
detail in Saunders et al (2000), Sections were blocked for 30 min
in normal rabbit serum (NRS, Diagnostics Scotland, Carluke)
diluted 1:4 in TBS containing 5% BSA (NRS/TBS/BSA), rinsed
brieﬂy in TBS and an avidin biotin block performed using reagents
from Vector (Peterborough, UK). Anti-ERb antibody was diluted
1:40 in NRS/TBS and incubated on sections overnight at 48C.
Sections were washed twice for 5 min each time in TBS and incu-
bated with rabbit anti mouse, (Dako, Cambridge, UK) diluted
1:500 in NRS/TBS/BSA. Thereafter, bound antibodies were visua-
lized by incubation with 3,3'-diaminobenzidine tetra-hydrochloride
(liquid DAB cat K3468, DAKO). Sections were counterstained with
haematoxylin.
Images were captured using an Olympus Provis microscope
(Olympus Optical Co, London, UK) equipped with a Kodak
DCS330 camera (Eastman Kodak Co., Rochester, NY, USA), stored
on a Macintosh PowerPC computer and assembled using Photo-
shop 5.5 (Adobe, Mountain View, CA, USA).
Quantitation of immunohistochemical staining
Quantitation was based on a scoring system reported in detail
previously (Allred et al, 1998; Leake et al, 2000). This method is
based on a composite additive score of intensity 0–3 and propor-
tion of malignant epithelial cells staining 0–5. This gives a range
from 0–8 for each tissue. Samples were analyzed using the SPSS
package (version 10 for Macintosh; SPSS Inc, Chicago, IL, USA)
and plotted as a box and whisker plot. No correlation between
ERa and ERb scores was detected.
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Detection of mRNAs for ERa and ERb in breast cancer
samples
All samples tested (n=9) were positive for ERb following RT–PCR
(Figure 1). This signal always appeared greater than those for ERa
and was present in both ERa positive and negative samples. Actin
was ampliﬁed from all samples although the efﬁciency of the reac-
tion was variable.
Speciﬁcity of antisera and extraction of ER proteins from
breast cancer biopsies
On Western blots (Figure 2) antibodies directed against ERa and
ERb bound to either recombinant ERa or recombinant ERb
protein depending upon the isotype to which they were directed.
These results were consistent with previously published data (Saun-
ders et al, 2000); no binding of the ERb speciﬁc monoclonal to
ERa was observed (Figure 2, lower panel, lane a). The anti-hERb
monoclonal that was directed against a peptide at the C-terminus
of hERb bound to both short (Mosselman et al, 1996) and long
(Ogawa et al, 1998a) forms of ERb. This result is consistent with
data that has demonstrated that the difference in size of the long
and short forms of ERb is due to use of alternative start sites for
translation within the full length mRNA and that the C-termini
of both proteins are identical.
Tissuebiopsiedfromeight tumours,thatwerehistologicallyshown
to be cancers, were also examined. The predominant form of the ERa
protein (Figure 2, upper panel) extracted from all biopsies migrated
with an apparent molecular size (*66 Kd) identical to recombinant
ERa run in a parallel lane (a). In only two samples (lanes 6 and 7)
did we see evidence of expression of shorter/variant ERa proteins.
The amount of ERb protein detected in extracts from cancer
biopsies was highly variable (Figure 2 lower panel). It was notable
that in six of the eight samples proteins migrating with apparent
molecular sizes corresponding to both long (*59 Kd) and short
(53 Kd) ERb were present. We have found that this antibody
recognizes ERb protein extracted from human ovary, prostate
(Saunders et al, 2000) endometrium and testis and human cell lines
(MCF-7, Ishikawa, unpublished observations). In breast tumour
samples that appeared to contain high levels of expression of full
length ERb (numbers 1, 3, 4, 7, 8) several lower molecular weight
protein species with apparent molecular weights from 32 to 45 Kd
were detected.
Immunolocalization of oestrogen receptors
Typical examples of immunostaining for ERa and ERb are shown
in Figures 3 and 4 respectively. Staining for ERa (Figure 3) was
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Figure 1 Detection of oestrogen receptor mRNAs by RT–PCR. (A)
ERb,( B)E R a,( C) Alpha-actin. In all panels, lane M 100 bp ladders, lanes
1–9 breast tumour samples, the negative control lane (7) contained a
sample prepared without reverse transcriptase. Note that although a
cDNA speciﬁc for ERb was ampliﬁed from all samples, the amount of
ERa cDNA ampliﬁed from the same sample set was highly variable.
ERa
a ßL ßs 1 2 3 4 5 6 7 8
— 120
— 84
— 52
— 36 
— 30
ERb
ßL ßs a 1234567 8
— 120
— 84
— 52
— 36 
— 30
Figure 2 Western analysis of proteins extracted from breast cancer
samples. Proteins were separated, blotted and incubated with antibodies
directed against ERa (upper panel) or ERb (lower panel). The anti-ERa anti-
body bound to recombinant hERa but not to recombinant hERb (bs, bL).
The anti-ERb1 antibody bound to both long (bL) and short (bs) forms of
recombinant hERb but not to recombinant hERa (a). Proteins migrating
with the same apparent molecular size as recombinant ERa (a, upper panel,
arrowhead) were detected in all breast samples (lanes 1 to 8, note identical
samples were used for both gels and are loaded in the same order). In sam-
ple numbers 6 and 7 additional lower molecular weight forms of ERa were
present. Variable amounts of ERb proteins were detected in the same sam-
ples. Proteins migrating with the same apparent molecular size as both long
and short forms of ERb proteins (arrowheads) were detected in breast
sample numbers 1, 3, 4, 6, 7, 8; additional lower molecular weight variants
were present in these same extracts but samples 2 and 5 lacked signiﬁcant
levels of ERb.
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nant epithelium (insets A' and B') in this tissue series. Note that
the malignant tissues illustrated in Figure 4A,B are the same as
those in Figure 3A,B (codes 5580 and 5667 respectively) and clearly
illustrate that ERa expression (Figure 3) can occur in the presence
(Figure 4A) or absence (Figure 4B) of ERb. Expression of ERb was
almost exclusively nuclear and often appeared granular and hetero-
geneous (Figure 4A'). Expression of ERb was noted in a wider
range of cells than was ERa and was found in non-malignant
components of the tumour including normal glandular elements
(Figure 4D arrows), blood vessels, adipose tissue and stromal cells
(asterisks) as well as in non-invasive intraduct cancers (Figure 4C).
Quantitation of immunohistochemical staining
Most of the tumours (48 out of 51) displayed staining for ERb in
malignant epithelium with a range of scoring between 2 and 7
(median score 4.5). ERa staining was found in 41 out of 50
tumours with a range of scoring between 6 and 8 (median score
7.5). Quantitatively it was possible to identify ERa-positive, ERb-
positive tumours (38 out of 51, Figures 3A and 4A) as well as
ERa-positive, ERb-negative tumours (3 out of 51, Figure 3B
compared with Figure 4B; 2 out of 51). ERa-negative, ERb-positive
tumours were detected (10 out of 51) but we observed no double
negatives. There was no quantitative relationship between immu-
nohistochemical scores for ERa and ERb (Figure 5).
DISCUSSION
Many breast cancers, like the normal tissue from which they are
derived, appear sensitive tooestrogens. The major action of oestrogen
appears to be mediated by speciﬁc receptor proteins that act as nucle-
ar transcription factors. Until recently, studies have concentrated on
the ERa member of the family and these have clearly demonstrated
the involvement of the protein in maintaining the growth of
hormone sensitive tumours. As a consequence ERa measurements
have been used to select patients for endocrine therapy and the
protein has become a therapeutic target by which to treat patients
with breast cancer. Nevertheless there have been paradoxical observa-
tions such as tumours regressing following endocrine deprivation
therapy in apparently ERa negative disease. Oestrogen responses in
ERa knockout mice and the differential effects of anti-oestrogens in
tissues and tumours were also unexplained.
Our ability to correlate ER status with outcome of therapy has
been complicated by the ﬁnding of a second oestrogen receptor
(ERb) which can bind oestrogens including oestradiol and tamox-
ifen with high afﬁnity (Kuiper et al, 1996, 1997; Mosselman et al,
1996). As a result there has been a major effort to delineate the role
of ERb in the natural history of breast cancer. Many papers have
reported that the mRNAs for both ERa and ERb are expressed
in breast cancer cell lines (Watanabe et al, 1997; Moore et al,
1998; Vladusic et al, 2000), in breast cancer tissue (Dotzlaw et al,
1997) and in the normal human and rodent mammary gland
(Moore et al, 1998; Saji et al, 2000). Studies that have compared
levels of expression of the mRNAs encoding the two receptors have
reported that the amount of ERb mRNA does not appear to be
correlated with that of ERa (Dotzlaw et al, 1997; Iwao et al,
2000; Vladusic et al, 2000) consistent with expression of the recep-
tors by different genes (Enmark et al, 1997). Some studies have
reported that up-regulation/over expression of ERb mRNA may
be correlated with development of oestrogen-independent tumour
growth and a poor prognosis (Speirs et al, 1999; Iwao et al, 2000).
Modelling studies using ERa have deﬁned the amino acids with-
in the protein which interact with natural as well as synthetic
oestrogens and anti-oestrogens (Ekena et al, 1997). The major
determinants of ligand binding are conserved between ERa and
ERb consistent with their ability of both to bind oestradiol (Kuiper
et al, 1997). Barkhem et al (1998) have used cell lines stabily trans-
fected with either ERa or ERb to test the afﬁnity and potency of
widely used anti-oestrogens including tamoxifen, raloxiﬁne and
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Figure 3 Immunoexpression of ERa in human breast cancers. Nuclear expression of ERa was largely conﬁned to malignant epithelium in the 40 samples in
which it was detected; intensity was variable. (A) example of intense immunostaining (sample code 5580); (B) sample code 5667, magniﬁcation 620, insets
A' and B' show higher power magniﬁcation of the same tissue samples.
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more different to that of ERa than can be anticipated from the
primary sequence. Recently novel non-steroidal ligands that show
subtype speciﬁc binding afﬁnity and transcriptional potency have
been identiﬁed (Sun et al, 1999) and ligand-dependent differences
in the ability of ERa and ERb to recruit co-activators following
exposure to xenoestrogens described (Routledge et al, 2000). ER-
driven gene activation can be determined by the formation of
homo- or hetero-dimers, the cell type, and whether the ligand-acti-
vated receptors bind to a promotor containing ERE or an AP-1 site
(Watanabe et al, 1997; Jones et al, 1999). Furthermore the experi-
ence with studies on ERa has been that mRNA is not necessarily
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Figure 4 Immunoexpression of ERb in human breast tissues. Nuclear expression of ERb protein was detected in 94% of the samples examined. (A,B)
show examples of immunopositive (A, code 5580) and immunonegative (B, code 5667) staining of malignant tissue. Expression of ERb was also noted in
non-invasive ductal cancer (C) and in epithelial (D, arrowheads) and stromal (D, asterisks) cells in areas of breast not associated with malignant growth.
(A,B), Magniﬁcation 610, bar=100 mM, insets A' and B' are from the same tissues as A and B, magniﬁcation 640, bar=50 mM.( C, D) Magniﬁcation
640, bar=50 mM.
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British Journal of Cancer (2002) 86(2), 250–256 ã 2002 The Cancer Research Campaigntranslated into protein make it essential that assays for ERb are
performed at the level of protein.
The monoclonal antibody used to detect ERb in the present study
was raised against a peptide at the C-terminus of human ERb1
(Mosselman et al, 1996; Moore et al, 1998). This peptide is not
conserved in any of the ERb variants formed by alternative splicing
of the F domain of the protein (Moore et al, 1998; Ogawa et al,
1998b) and does not recognize recombinant ERb2/bcx on Western
blots (unpublished observations). Similarly Western blotting indi-
cated that the monoclonal antibody identiﬁed ERb but not ERa in
breast cancers. Most of the ERb1 protein detected in the extracts
from the breast cancers migrated with the same apparent size as
the ‘long’ and ‘short’ forms of recombinant ERb1, which are formed
by translation from different ATGs in the mRNA (Mosselman et al,
1996; Ogawa et al, 1998a). We did not detect proteins corresponding
in size to those that could be translated from mRNAs deleted in
exons 5 or 6 (Lu et al, 1998; Brandenberger et al, 1999) predicted
to be 16.8 and 13 Kd respectively. The most prominent proteins
other than full length ERb1 migrated between 30 and 36 Kd these
could represent use of alternative start sites, translation from an
exon 2 deleted mRNA (*35 Kd) or translation of protein from
mRNA deleted for both exons 5 and 6 (AF074599) which is
predicted to be *43 Kd (short) or *49 Kd (long) from the mRNA
sequence. It is notable that mRNAs corresponding to alternatively
spliced forms of ERb have been detected in breast cancer tissues
and cell lines (Lu et al, 1998; Moore et al, 1998; Vladusic et al,
1998; Iwao et al, 2000) as well as in normal human tissues (Ogawa
et al, 1998b; Scobie et al, 2001). Furthermore, monoclonal antibo-
dies directed against the N terminus of ERb have detected
expression of proteins other than full length ERb in breast cancer
cell lines (Fuqua et al, 1999) which might have been formed by
translation of alternatively spliced mRNAs. During the course of
the present study we found that recombinant ERb proteins (both
from commercial sources and prepared in house) degrade if
subjected to a single freeze-thaw cycle or following prolonged
storage even at low temperatures (7708C). Therefore although
considerable attention was paid to extraction of the breast tumour
samples and to the storage of extracts we believe that the most likely
explanation for the lower molecular weight bands identiﬁed in
samples containing the highest levels of ERb1 is that these are break-
down products of the full length protein which have formed during
handling of the protein extracts.
We have used our ERb1speciﬁc monoclonal antibody toimmuno-
localize ERb1 in a series of breast cancers as well as in other human
and primate tissues (Saunders et al, 2000; Scobie et al, 2001). The
present study has demonstrated the presence of ERb1 in cell nuclei
not only the malignant epithelium but also non-malignant elements
of most breast cancers. The qualitative and quantitative expression of
ERb was independent of that of ERa. We have observed that ERb1
was also expressed in multiple types of non-cancer cells within the
breast tissue and this will therefore further complicate the assessment
of ERb status. For example, methods such as RT–PCR or Western
blotting which use tissue extracts may contain a contribution from
cells other than those derived from the malignant component of
the tumour. It will therefore be important to quantify expression in
different compartments of the breast separately. This precludes the
simple use of Western and Northern blotting together with other
technologies in which tissue is homogenized and extracted.
Whilst our studies were being written up three reports describing
immunolocalization of ERb to breast cancer samples were published.
Mann et al (2001) used a rabbit polyclonal antibody directed against
the N-terminus of human ERb on formalin ﬁxed samples; on the
Western blot shown in their article multiple bands are shown, the
most prominent of which appeared shorter than the recombinant
standard and this may reﬂect degradation of protein in their extracts
or non-speciﬁc reactivity of the antibody used. In their paper immu-
nopositive staining of human breast cancer for ERb was present in 66
and 70% of the two sets of samples reported but no mention was
made of immunopositive staining of cells other than those of the
malignancy. The authors mentioned the potential cross-reactivity of
their antibody with isoforms of ERb including ERbcx (Ogawa et al,
1998b) which will not occur with the antibody used in the current
study. It is notable that the polyclonal rabbit antibody used by Omoto
et al (2001) is raised to an identical part of the ERb1 protein to our
monoclonal and we would therefore expect similar results to our
own. In their study they used frozen sections of tissue and found that
only 59% (52 out of 88) were positive for ERb, with only 38% of the
ERa negative samples expressing the ERb subtype. This proportion is
much lower than in the current study or in the tissue set studied by
Jarvinen et al (2000) who used frozen sections ﬁxed brieﬂy with
Zamboni’s, and found 60% of cancers contained ERb1 positive cells
using a commercial polyclonal antibody raised to the same region of
the protein. The need to use frozen sections clearly limits the utility of
these antibodies and highlights an important difference with the
reagent used in the present study which appearscapable of identifying
ERb1inmaterial ﬁxedby formalin,methacarn (unpublished observa-
tions) or Bouins (Saunders et al, 2000). In studies using ﬁxed samples
from human tissues including ovary, placenta, vas deferens, testis and
endometrium we have used monoclonal and polyclonal antibodies to
localize ERb proteins (Saunders et al, 2000; Critchley et al, 2001;
Scobie et al, 2001). In all cases we ﬁnd the protein to be nuclear in
location in agreement with the ﬁndings using ﬁxed tissues of human
breast (present study) the only exceptions being dividing cells, and
some myoid cell types where background staining of the cytoplasm
associated with the secondary antibodies was a problem. We have
detected cytoplasmic staining using some commercial anti ERb anti-
bodies especially those that have not been afﬁnity puriﬁed and with
some secondary antibodies especially those raised in goats (unpub-
lished observations). These ﬁndings may explain some of the
cytoplasmic staining seen in the ﬁgures published by others (Jarvinen
et al, 2000; Mann et al, 2001; Omoto et al, 2001).
In conclusion, we believe that to assess the responsiveness of
breast cancers to oestrogenic and anti-oestrogenic stimuli it will
be necessary to measure both ERa and ERb at the level of protein.
The presence of ERb in both malignant and non-malignant
components of breast tumours means that assessments in indivi-
dual compartments may also be required. This approach is being
utilized in our ongoing studies.
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Figure 5 Quantiﬁcation of immunoexpression for ER isotypes. Box and
whisker plot summarising the relationship between score for ERa (x-axis)
and ERb (y-axis) for each sample. Solid horizontal line shows the median
for the data, the top of the box the 25th percentile, the bottom the
75th percentile and the additional lines the range of the data. Note that
there were no samples with an ERa score of 1 to 5.
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